Equities

Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)89.80
  • Today's Change0.80 / 0.90%
  • Shares traded1.52k
  • 1 Year change+108.35%
  • Beta0.7938
Data delayed at least 15 minutes, as of May 10 2024 08:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-123.07m
  • Incorporated2011
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alligator Bioscience AB55.49m-248.80m639.79m55.00------11.53-0.4848-0.48480.0999-0.07720.5289--8.07956,741.40-237.13-73.26---91.33-----448.35-811.68---104.20----62.7816.60-28.53---20.34--
Cantargia AB0.00-280.03m663.11m22.00--3.93-----1.65-1.650.000.91860.00----0.00-80.18-55.08-100.27-61.35------------0.00------24.69------
Orexo AB638.60m-128.40m666.44m116.00--11.23--1.04-3.73-3.7318.551.710.67381.522.885,505,173.00-13.55-6.41-20.60-9.9986.0986.76-20.11-11.831.580.36040.8894--2.32-3.9927.76--25.77--
Intellego Technologies AB186.49m59.60m777.40m62.0012.665.1412.314.172.332.337.355.740.88413.873.693,007,968.0028.26--44.00--68.73--31.96--2.075.820.1684--222.74--493.56------
Nightingale Health Oyj42.74m-211.22m846.65m81.00--1.23--19.81-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Moberg Pharma AB (publ)0.00-21.09m957.90m----1.54-----1.20-1.200.0021.840.00-------3.52---3.66----------3.04--0.0077---100.00---34.26------
BioPorto A/S48.54m-88.32m969.14m31.00--10.27--19.97-0.1605-0.16050.08830.15850.3123.4011.96998,645.20-56.77-71.10-79.27-96.5565.1963.38-181.95-239.223.09-1,718.970.1076--6.873.5425.81---51.56--
Vistin Pharma ASA438.42m56.24m1.01bn77.0017.903.3913.592.301.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Diamyd Medical AB282.00k-120.18m1.02bn26.00--5.53--3,625.87-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
XSpray Pharma AB (publ)0.00-179.67m1.06bn26.00--1.92-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Cereno Scientific AB0.00-48.11m1.10bn5.00--4.22-----0.241-0.2410.000.92580.00----0.00-19.22-16.81-20.75-18.26-----------12.920.1734-------73.95--44.79--
Infant Bacterial Therapeutics AB0.00-123.07m1.16bn8.00--3.93-----9.90-9.900.0022.650.00----0.00-35.11-16.11-38.65-16.69------------0.00-------88.03------
SyntheticMR AB (publ)89.21m10.01m1.19bn37.00116.5610.1873.0913.320.24450.24452.172.800.6599--1.612,411,162.007.417.198.898.85105.78106.7411.229.08--14.130.010721.5030.6713.0570.34-7.3326.79--
Arcticzymes Technologies ASA118.96m18.72m1.21bn61.0064.163.9248.1210.160.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Photocure ASA500.75m267.05k1.60bn106.008,217.273.3257.233.200.00720.007218.5817.790.70010.82039.37--0.0375-3.090.0429-3.5694.7893.640.0535-5.194.32--0.00--27.3522.50100.37--49.83--
Devyser Diagnostics AB169.30m-53.60m1.61bn118.00--4.19--9.52-3.31-3.3110.4623.650.3351.595.531,434,746.00-10.65-8.97-12.00-10.1585.5380.14-31.78-23.915.11--0.1626--33.7128.59-16.64--44.59--
Data as of May 10 2024. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK

Institutional shareholders

40.66%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Jul 20231.34m10.32%
Keel Capital ABas of 08 Jan 2024666.05k5.12%
AMF Fonder ABas of 31 Jul 2023601.90k4.62%
Tredje AP-fondenas of 31 Jul 2023601.89k4.62%
Premier Fund Managers Ltd.as of 30 Nov 2023581.73k4.47%
Swedbank Robur Fonder ABas of 31 Dec 2022540.00k4.15%
SEB Investment Management ABas of 31 Jul 2023419.52k3.22%
�landsbanken Fondbolag AB (Sweden)as of 31 Jul 2023395.35k3.04%
Handelsbanken Fonder ABas of 31 Mar 202481.31k0.63%
Tiff Advisory Services LLCas of 31 Dec 202361.77k0.47%
More ▼
Data from 29 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.